Trial Profile
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Evacetrapib (Primary) ; Atorvastatin; Ezetimibe
- Indications Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Acronyms ACCENTUATE
- Sponsors Eli Lilly and Company
- 01 Feb 2022 Results from ctp:700008441 and ctp:248832 published in the Arteriosclerosis Thrombosis and Vascular Biology
- 12 Oct 2015 Status changed from recruiting to discontinued following premature cessation of the large cardiovascular outcomes trial (ACCELERATE) evaluating the impact of evacetrapib due to clinical futility, according to results published in the Atherosclerosis Journal.
- 20 May 2015 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.